- Home
- NCIQ vs OGEN Comparison
NCIQ vs OGEN Comparison
Compare NCIQ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCIQ
- OGEN
- Stock Information
- Founded
- NCIQ N/A
- OGEN 1996
- Country
- NCIQ United States
- OGEN United States
- Employees
- NCIQ N/A
- OGEN N/A
- Industry
- NCIQ
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NCIQ
- OGEN Health Care
- Exchange
- NCIQ Nasdaq
- OGEN Nasdaq
- Market Cap
- NCIQ N/A
- OGEN 4.6M
- IPO Year
- NCIQ N/A
- OGEN N/A
- Fundamental
- Price
- NCIQ $21.17
- OGEN $0.19
- Analyst Decision
- NCIQ
- OGEN
- Analyst Count
- NCIQ 0
- OGEN 0
- Target Price
- NCIQ N/A
- OGEN N/A
- AVG Volume (30 Days)
- NCIQ N/A
- OGEN 436.4K
- Earning Date
- NCIQ N/A
- OGEN 05-14-2025
- Dividend Yield
- NCIQ N/A
- OGEN N/A
- EPS Growth
- NCIQ N/A
- OGEN N/A
- EPS
- NCIQ N/A
- OGEN N/A
- Revenue
- NCIQ N/A
- OGEN N/A
- Revenue This Year
- NCIQ N/A
- OGEN N/A
- Revenue Next Year
- NCIQ N/A
- OGEN N/A
- P/E Ratio
- NCIQ N/A
- OGEN N/A
- Revenue Growth
- NCIQ N/A
- OGEN N/A
- 52 Week Low
- NCIQ N/A
- OGEN $0.18
- 52 Week High
- NCIQ N/A
- OGEN $3.43
- Technical
- Relative Strength Index (RSI)
- NCIQ N/A
- OGEN 26.46
- Support Level
- NCIQ N/A
- OGEN $0.19
- Resistance Level
- NCIQ N/A
- OGEN $0.22
- Average True Range (ATR)
- NCIQ 0.00
- OGEN 0.02
- MACD
- NCIQ 0.00
- OGEN -0.01
- Stochastic Oscillator
- NCIQ 0.00
- OGEN 10.97
Stock Price Comparison Chart: NCIQ vs OGEN
■ NCIQ
■ OGEN
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Share on Social Networks:
0